Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel Antibody And Use In Diagnosis And Therapy Of Arthropathies

a technology of arthropathies and antibodies, applied in the field of new antibody and use in diagnosis and therapy of arthropathies, can solve the problems of increasing the risk of serious infections and malignancies, inconsistent effectiveness, and increasing the number of patients that fail anti-tnf therapy

Inactive Publication Date: 2016-08-11
QUEEN MARY UNIV OF LONDON
View PDF0 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These treatments however, are not consistently effective and the number of patients that fail anti-TNF therapy is increasing.
Especially for anti-TNFa treatment there is a risk of serious infections and malignancies.
These systemic side effects could be minimised by the development of technologies to target therapeutic agents specifically to the inflamed tissues, but has so far been impeded by the lack of proper target epitope(s) that would be present uniquely in the diseased joint and not in the healthy joint.
The combined activities of MMP and ROS may be the cause of the excessive degradation of the extracellular matrix leading to cartilage destruction.
Over activation of the inflammatory pathway leads to synovitis, joint damage and destruction.
The efficacy of anti-TNFa monoclonal antibodies (Infliximab and Adalimumab), soluble p75 TNF receptors (Etanercept) and IL-1 receptor antagonist (Anakinra) in the treatment of RA patients unresponsive to traditional therapy is now well established but unfortunately might be associated with an increase in serious infection and malignancies.
Systemic administration of sufficient blocking agents that can block the local high physiological concentration will likely cause severe side effects.
This approach is significantly different from targeting citrullinated peptides that appear as a good biomarker for disease in RA but could not be used as a targeting molecule as its tissue expression is not joint specific.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel Antibody And Use In Diagnosis And Therapy Of Arthropathies
  • Novel Antibody And Use In Diagnosis And Therapy Of Arthropathies
  • Novel Antibody And Use In Diagnosis And Therapy Of Arthropathies

Examples

Experimental program
Comparison scheme
Effect test

example 2

Selection of Anti-Modified CII scFv from Phase-Display Library

[0087]Phage display antibody technology (Winter G et al, Annu. Rev. Immunol. 12: 433-455, 1994) was used to raise a single chain fragment variable (scFv) that binds only to CII that has been post-translationally modified by free radicals.

[0088]A human semi-synthetic scFv library constructed from a single human framework for VH (DP-47 and JH4) and VL (DPK9 and JK1) was employed, in which diversity was incorporated in CDR3 and CDR2 (de Wildt R. M et al, Nat. Biotechnol. 18(9): 989-994, 2000). To select for phage binding to modified CII and not to native non-modified CII, subtractive selection was performed using native non-modified CII for subtraction. HOCl modified CII was used as a target for panning as binding to HOCl modified CII was strongest in RA sera (Nissim A, 2005). Glycated CII was used in parallel. Briefly, immunotubes (Nunc-Immuno Tubes, Maxi-Sorp, Nunc, Denmark) were coated with 10 μg / ml CII in phosphate-buffe...

example 3

Screening and Sequencing of Modified CII-Specific Phage Clones

[0089]Screening for positive anti-modified CII phage clones was first performed by enzyme-linked immunosorbent assay (ELISA), as previously described (Harrison J. L, 1996). Microtiter plate (Nunc, Paisley, UK) wells were coated with 10 μg / ml native or modified CII and incubated with 100 μl phage suspension for 90 minutes. In addition, native and modified BSA were used as negative control. After removal of the supernatants, the amount of bound phage was determined using peroxidase-labeled anti-M13 antibodies (GE Healthcare: Ltd, Little Chalfont, Buckinghamshire) and developed by using 100 mM 3,3′5,5′ tetramethylbenzidine (TMB) as substrate. The reaction was monitored in an ELISA reader at 450 nm with a reference wavelength of 650 nm using GENios plate reader (TECAN, Theale Court, Reading UK) and Magellan software (TECAN, Theale Court, Reading UK)

[0090]The entire scFv DNA fragment of each modified CII bound phage clone was ...

example 4

Production and Purification of Anti-Modified CII-scFv

[0091]The reactive phage clones obtained from E. coli TG-1 bacteria were used to infect E. coli HB2151 non-suppressor bacterial strain to obtain soluble scFv. After overnight induction with 1 mM IPTG at 30° C., the antibody fragments, derived from the VH3 family, were harvested from the supernatant and periplasmic space as described (Harrison J. L, 1996) and purified on a protein A affinity column (GE Healthcare Ltd, Little Chalfont, Buckinghamshire). Binding of purified scFv to modified CII was first analyzed by ELISA as above except that mouse anti-myc tag antibody (Santa Cruz Biotechnology, INC, Wembley, UK) followed by anti-mouse-HRP conjugate (Sigma, Dorset, UK) were used to probe bound scFv.

Anti-Modified CII scFv Raised by Phage Display Human Antibody Library

[0092]After three rounds of subtractive selection 82 phage clones specific to either glycated CII or HOCl modified CII were selected out of which 42 clones had unique se...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
wavelengthaaaaaaaaaa
wavelengthaaaaaaaaaa
thickaaaaaaaaaa
Login to View More

Abstract

The present invention provides a composition comprising an antibody or fragment thereof against oxidised Collagen II (CII) in which the antibody or fragment thereof is conjugated to a pharmaceutically active moiety. The invention also provides a composition comprising an antibody or fragment thereof against oxidised Collagen II (CII) and a detectable label. The invention further provides the use of such compositions in medicine, in particular for the treatment of an arthropathy, and in methods of diagnosis.

Description

[0001]The present invention relates to a novel antibody and its use in the diagnosis and therapy of inflammatory diseases of the joints such as rheumatoid arthritis (RA) and osteoarthritis (OA).INTRODUCTION[0002]The final outcome of most rheumatic conditions, the leading cause of disabilities in the western world, is breakdown of articular cartilage. This breakdown is the final outcome of inflammatory events in both rheumatoid arthritis (RA) and osteoarthritis (OA) mediated by either influx of activated leukocytes (RA) or activated chondrocytes (OA). Pro-inflammatory cytokine blockade such as anti-TNFa and IL-1Ra is therefore currently used to treat arthritic conditions, mainly RA. These treatments however, are not consistently effective and the number of patients that fail anti-TNF therapy is increasing. Especially for anti-TNFa treatment there is a risk of serious infections and malignancies. These systemic side effects could be minimised by the development of technologies to targ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K47/48A61K51/10C07K16/18
CPCA61K47/48438A61K47/48538A61K47/48423C07K2317/569C07K2317/565C07K2317/76C07K16/18A61K51/1096A61K47/48415C07K2317/622C07K2317/55A61K47/6843A61K47/6811A61K47/6817A61K47/6813A61P19/02A61K47/6803A61K47/6851A61K47/6849
Inventor NISSIM, AHUVACHERNAJOVSKY, YUTIFAURHOLM, BJARNEPERRETT, DAVIDWINYARD, PAULHUGHES, CHRISTOPHERMATHER, STEPHENDELL'ACCIO, FRANCESCO
Owner QUEEN MARY UNIV OF LONDON
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com